Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacterial surface structures represent a broad category of complex molecules and assemblies located on the exterior of bacterial cells, including the peptidoglycan cell wall, lipopolysaccharides (LPS), capsules, S-layers, pili, and flagella (Silhavy et al., 2010, Cold Spring Harbor Perspectives in Biology). These structures are essential for maintaining bacterial cell shape, protecting against osmotic pressure, and facilitating interactions with the host environment, such as adhesion and colonization (Auer & Weibel, 2017, Nature Reviews Microbiology). In the context of infection, these components often function as Pathogen-Associated Molecular Patterns (PAMPs) that are recognized by the host's innate immune system via Pattern Recognition Receptors (PRRs) (Mogensen, 2009, Clinical Microbiology Reviews). Because many of these structures are unique to bacteria and absent in human cells, they are ideal targets for therapeutic intervention. For instance, beta-lactam antibiotics and glycopeptides target the synthesis of the peptidoglycan layer, leading to bacterial lysis (Kohanski et al., 2010, Nature Reviews Microbiology). Furthermore, surface polysaccharides are the primary components of many highly effective vaccines, such as those against Streptococcus pneumoniae and Haemophilus influenzae type b, which induce protective antibody responses (Pollard et al., 2009, Nature Reviews Immunology). However, the clinical utility of targeting these structures is increasingly challenged by the emergence of antimicrobial resistance and the potential for systemic inflammatory responses, such as the Jarisch-Herxheimer reaction, following the rapid release of bacterial components like endotoxins (Bryceson, 1970, Journal of Infectious Diseases).
Inhibition of cell wall biosynthesis, disruption of membrane integrity, neutralization of surface antigens, and induction of opsonophagocytosis.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterial surface structures.